{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:45Z","timestamp":1794047445992,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Majority of non-Hodgkin lymphoma (NHL) patients who achieve partial response (PR) or stable disease (SD) to CAR T-cell therapy (CAR T) on day +30 progress and only 30% achieve spontaneous complete response (CR). This study is the first to evaluate the role of consolidative radiotherapy (cRT) for residual fluorodeoxyglucose (FDG) activity on day +30 post- CAR T in NHL. We retrospectively reviewed 61 patients with NHL who received CAR T and achieved PR or SD on day +30. Progression-free survival (PFS), overall survival (OS), and local relapse-free survival (LRFS) were assessed from CAR T infusion. cRT was defined as comprehensive - treated all FDG-avid sites - or focal. Following day +30 positron emission tomography scan, 45 patients were observed and 16 received cRT. Fifteen (33%) observed patients achieved spontaneous CR, and 27 (60%) progressed with all relapses involving initial sites of residual FDG activity. Ten (63%) cRT patients achieved CR, and four (25%) progressed with no relapses in the irradiated sites. The 2-year LRFS was 100% in the cRT sites and 31% in the observed sites (P&lt;0.001). The 2-year PFS was 73% and 37% (P=0.025) and the 2-year OS was 78% and 43% (P=0.12) in the cRT and observation groups, respectively. Patients receiving comprehensive cRT (n=13) had superior 2- year PFS (83% vs. 37%; P=0.008) and 2-year OS (86% vs. 43%; P=0.047) compared to observed or focal cRT patients (n=48). NHL patients with residual FDG activity following CAR T are at high risk of local progression. cRT for residual FDG activity on day +30 post-CAR T appears to alter the pattern of relapse and improve LRFS and PFS.<\/jats:p>","DOI":"10.3324\/haematol.2023.283311","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T04:01:16Z","timestamp":1686801676000},"page":"2982-2992","source":"Crossref","is-referenced-by-count":19,"title":["Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma"],"prefix":"10.3324","volume":"108","author":[{"given":"Omran","family":"Saifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J","family":"Stish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Hathcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C","family":"Villasboas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamad Alhaj","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford S","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"53583","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"53584","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"53585","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Tam CS, Borchmann P. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22(10):1403-1415.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"53586","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022; 386(7):640-654.","DOI":"10.1056\/NEJMoa2116133"},{"key":"53587","doi-asserted-by":"crossref","unstructured":"Bishop MR, Dickinson M, Purtill D. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022; 386(7):629-639.","DOI":"10.1056\/NEJMoa2116596"},{"key":"53588","doi-asserted-by":"crossref","unstructured":"Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. 2018; 31(3):293-298.","DOI":"10.1016\/j.beha.2018.07.011"},{"key":"53589","doi-asserted-by":"crossref","unstructured":"Kuhnl A, Roddie C, Kirkwood AA. Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Adv. 2022; 6(1):321-326.","DOI":"10.1182\/bloodadvances.2021005807"},{"key":"53590","doi-asserted-by":"crossref","unstructured":"Chow VA, Gopal AK, Maloney DG. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019; 94(8):E209-E213.","DOI":"10.1002\/ajh.25505"},{"key":"53591","doi-asserted-by":"crossref","unstructured":"Martens C, Hodgson DC, Wells WA. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006; 64(4):1183-1187.","DOI":"10.1016\/j.ijrobp.2005.09.030"},{"key":"53592","doi-asserted-by":"crossref","unstructured":"Saifi O, Breen WG, Lester SC. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiother Oncol. 2022; 166:171-179.","DOI":"10.1016\/j.radonc.2021.11.031"},{"key":"53593","doi-asserted-by":"crossref","unstructured":"Figura NB, Robinson TJ, Sim AJ. Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy. Int J Radiat Oncol Biol Phys. 2021; 111(5):1145-1154.","DOI":"10.1016\/j.ijrobp.2021.06.038"},{"key":"53594","doi-asserted-by":"crossref","unstructured":"Held G, Murawski N, Ziepert M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014; 32(11):1112-1118.","DOI":"10.1200\/JCO.2013.51.4505"},{"key":"53595","doi-asserted-by":"crossref","unstructured":"Poeschel V, Held G, Ziepert M. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019; 394(10216):2271-2281.","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"53596","doi-asserted-by":"crossref","unstructured":"Held G, Zeynalova S, Murawski N. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013; 31(32):4115-4122.","DOI":"10.1200\/JCO.2012.48.0467"},{"key":"53597","doi-asserted-by":"crossref","unstructured":"Philip T, Armitage JO, Spitzer G. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987; 316(24):1493-1498.","DOI":"10.1056\/NEJM198706113162401"},{"key":"53598","doi-asserted-by":"crossref","unstructured":"Ng AK, Yahalom J, Goda JS. Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018; 100(3):652-669.","DOI":"10.1016\/j.ijrobp.2017.12.005"},{"key":"53599","doi-asserted-by":"crossref","unstructured":"Hoppe BS, Moskowitz CH, Filippa DA. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol. 2008; 26(11):1858-1864.","DOI":"10.1200\/JCO.2007.15.4773"},{"key":"53600","doi-asserted-by":"crossref","unstructured":"Saifi O, Breen WG, Lester SC. Don't put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2023; 116(5):999-1007.","DOI":"10.1016\/j.ijrobp.2022.12.017"},{"key":"53601","doi-asserted-by":"crossref","unstructured":"Saifi O, Breen W, Lester SC. The impact of radiation timing in peri-CAR T-cell therapy on local control for relapsed\/refractory B-cell non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2022; 114(3):S85-S86.","DOI":"10.1016\/j.ijrobp.2022.07.492"},{"key":"53602","doi-asserted-by":"crossref","unstructured":"Saifi O, Breen W, Lester S. In-field recurrences in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART). J Clin Oncol. 2022; 40(Suppl 16):S7556-7556.","DOI":"10.1200\/JCO.2022.40.16_suppl.7556"},{"key":"53603","doi-asserted-by":"crossref","unstructured":"Sim AJ, Jain MD, Figura NB. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2019; 105(5):1012-1021.","DOI":"10.1016\/j.ijrobp.2019.05.065"},{"key":"53604","doi-asserted-by":"crossref","unstructured":"Wright CM, LaRiviere MJ, Baron JA. Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2020; 108(1):178-188.","DOI":"10.1016\/j.ijrobp.2020.05.014"},{"key":"53605","doi-asserted-by":"crossref","unstructured":"Pinnix CC, Gunther JR, Dabaja BS. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020; 4(13):2871-2883.","DOI":"10.1182\/bloodadvances.2020001837"},{"key":"53606","doi-asserted-by":"crossref","unstructured":"Ladbury C, Kambhampati S, Othman T. Role of salvage radiation treatment of relapses in relapsed\/refractory diffuse large B cell lymphoma post-autologous stem cell transplant. Int J Radiat Oncol Biol Phys. 2022; 113(3):594-601.","DOI":"10.1016\/j.ijrobp.2022.02.015"},{"key":"53607","doi-asserted-by":"crossref","unstructured":"Saifi O, Breen W, Lester SC. Comprehensive salvage radiotherapy for limited relapsed B-cell non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell therapy. Int J Radiat Oncol Biol Phys. 2022; 114(3):S56.","DOI":"10.1016\/j.ijrobp.2022.07.436"},{"key":"53608","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"53609","doi-asserted-by":"crossref","unstructured":"Reyes F, Lepage E, Ganem G. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005; 352(12):1197-1205.","DOI":"10.1056\/NEJMoa042040"},{"key":"53610","doi-asserted-by":"crossref","unstructured":"Bonnet C, Fillet G, Mounier N. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25(7):787-792.","DOI":"10.1200\/JCO.2006.07.0722"},{"key":"53611","doi-asserted-by":"crossref","unstructured":"Lamy T, Damaj G, Soubeyran P. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018; 131(2):174-181.","DOI":"10.1182\/blood-2017-07-793984"},{"key":"53612","doi-asserted-by":"crossref","unstructured":"Horning SJ, Weller E, Kim K. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004; 22(15):3032-3038.","DOI":"10.1200\/JCO.2004.06.088"},{"key":"53613","doi-asserted-by":"crossref","unstructured":"Gomez DR, Blumenschein GR, Lee JJ. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016; 17(12):1672-1682.","DOI":"10.1016\/S1470-2045(16)30532-0"},{"key":"53614","doi-asserted-by":"crossref","unstructured":"Palma DA, Olson R, Harrow S. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020; 38(25):2830-2838.","DOI":"10.1200\/JCO.20.00818"},{"key":"53615","doi-asserted-by":"crossref","unstructured":"Miller TP, Dahlberg S, Cassady JR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339(1):21-26.","DOI":"10.1056\/NEJM199807023390104"},{"key":"53616","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Murawski N, Ziepert M. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA. J Clin Oncol. 2018; 36(Suppl 15):S7574-7574.","DOI":"10.1200\/JCO.2018.36.15_suppl.7574"},{"key":"53617","doi-asserted-by":"crossref","unstructured":"Persky DO, Li H, Stephens DM. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020; 38(26):3003-3011.","DOI":"10.1200\/JCO.20.00999"},{"key":"53618","doi-asserted-by":"crossref","unstructured":"Freeman CL, Savage KJ, Villa DR. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021; 137(7):929-938.","DOI":"10.1182\/blood.2020005846"},{"key":"53619","doi-asserted-by":"crossref","unstructured":"Phan J, Mazloom A, Medeiros LJ. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010; 28(27):4170-4176.","DOI":"10.1200\/JCO.2009.27.3441"},{"key":"53620","doi-asserted-by":"crossref","unstructured":"Philip T, Guglielmi C, Hagenbeek A. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23):1540-1545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"53621","doi-asserted-by":"crossref","unstructured":"Mundt AJ, Williams SF, Hallahan D. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy. Int J Radiat Oncol Biol Phys. 1997; 39(3):617-625.","DOI":"10.1016\/S0360-3016(97)00379-9"},{"key":"53622","doi-asserted-by":"crossref","unstructured":"Vose JM, Zhang MJ, Rowlings PA. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001; 19(2):406-413.","DOI":"10.1200\/JCO.2001.19.2.406"},{"key":"53623","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2001; 7(8):446-453.","DOI":"10.1016\/S1083-8791(01)80012-4"},{"key":"53624","doi-asserted-by":"crossref","unstructured":"Hoppe BS, Moskowitz CH, Zhang Z. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009; 43(12):941-948.","DOI":"10.1038\/bmt.2008.408"},{"key":"53625","doi-asserted-by":"crossref","unstructured":"Biswas T, Dhakal S, Chen R. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2010; 77(1):79-85.","DOI":"10.1016\/j.ijrobp.2009.04.036"},{"key":"53626","doi-asserted-by":"crossref","unstructured":"Wendland MM, Smith DC, Boucher KM. The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Am J Clin Oncol. 2007; 30(2):156-162.","DOI":"10.1097\/01.coc.0000251242.32763.35"},{"key":"53627","doi-asserted-by":"crossref","unstructured":"Wilke C, Cao Q, Dusenbery KE. Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017; 99(1):94-102.","DOI":"10.1016\/j.ijrobp.2017.05.007"},{"key":"53628","doi-asserted-by":"crossref","unstructured":"Yu Q, Zhang X, Wang N. Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma. Radiother Oncol. 2022; 177:53-60.","DOI":"10.1016\/j.radonc.2022.10.018"},{"key":"53629","doi-asserted-by":"crossref","unstructured":"Smith EL, Mailankody S, Staehr M. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol Res. 2019; 7(7):1047-1053.","DOI":"10.1158\/2326-6066.CIR-18-0551"},{"key":"53630","doi-asserted-by":"crossref","unstructured":"Kostopoulos N, Bedgi S, Krimitza E. Radiation therapy for bridging and improving CAR-T cell therapy. Int J Radiat Oncol Biol Phys. 2022; 114(3):S83-S84.","DOI":"10.1016\/j.ijrobp.2022.07.488"},{"key":"53631","doi-asserted-by":"crossref","unstructured":"DeSelm C, Palomba ML, Yahalom J. Low-dose radiation conditioning Eenables CAR T cells to mitigate antigen escape. Mol Ther. 2018; 26(11):2542-2552.","DOI":"10.1016\/j.ymthe.2018.09.008"},{"key":"53632","doi-asserted-by":"crossref","unstructured":"Breen WG, Hathcock MA, Young JR. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET\/CT. J Hematol Oncol. 2022; 15(1):36.","DOI":"10.1186\/s13045-022-01256-w"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283311\/75703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283311\/76217","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11115\/75703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:13Z","timestamp":1794045853000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283311","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}